Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1701-1706

  Shen, Aling ^a   Lin, Jiumao ^a   Chen, Youqin ^c   Lin, Wei ^a   Liu, Liya ^a   Hong, Zhenfeng ^a   Sferra, Thomas J ^c   Peng, Jun ^a,b  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd   (China)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anti cancer treatment; Pien Tze Huang; Signaling pathway; Traditional Chinese medicine; Tumor angiogenesis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CHINESE DRUG; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; PIEN TZE HUANG; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CAPILLARY DENSITY; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUGS, CHINESE HERBAL; FIBROBLAST GROWTH FACTORS; HT29 CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882711353     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2609     Document Type: Article

References (41)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
3. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1: 27-31, 1995.
4. Folkman J: Angiogenesis. Annu Rev Med 57: 1-18, 2006.
5. Cook KM and Figg WD: Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60: 222-243, 2010.
6. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer related inflammation. Nature 454: 436-444, 2008.
7. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912, 2008.
8. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051, 1987.
9. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial award lecture. Cancer Res 46: 467-473, 1986.
10. Robert S and Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
11. Sun W: Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 5: 63, 2012.
12. Weis SM and Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370, 2011.
13. Qian WF, Guan WX, Gao Y, Tan JF, Qiao ZM, Huang H and Xia CL: Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. Braz J Med Biol Res 44: 1222-1230, 2011.
14. Berra E, Pagès G and Pouysségur J: MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139-145, 2000.
15. Stromblad S and Cheresh DA: Integrins, angiogenesis and vascular cell survival. Chem Biol 3: 881-885, 1996.
16. Breier G and Risau W: The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 6: 454-456, 1996.
17. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
18. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14, 2002.
19. Jain RK: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29: 3-9, 2002.
20. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
21. Ziche M and Morbidelli L: Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw 20: 164-170, 2009.
22. Cooke JP and Losordo DW: Nitric oxide and angiogenesis. Circulation 105: 2133-2135, 2002.
23. Eikesdal HP and Kalluri R: Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 19: 310-317, 2009.
24. Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep 17: 215-234, 2000.
25. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
26. Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. EMBO Rep 10: 194-200, 2009.
27. Chinese Pharmacopoeia Commission: Pharmacopoeia of the Peoples Republic of China. Chinese Medical Science and Technology Press 1: 573-575, 2010.
28. Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF, Sferra TJ and Peng J: Pien Tze Huang-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3. Chin J Integr Med 17: 685-690, 2011.
29. Zhuang QC, Hong F, Shen AL, Zheng LP, Zeng JW, Lin W, Chen YQ, Sferra TJ, Hong ZF and Peng J: Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model. Int J Oncol 40: 1569-1574, 2012.
30. Shen AL, Hong F, Liu LY, Lin JM, Zhuang QC, Hong ZF and Peng J: Effects of Pien Tze Huang on angiogenesis in vivo and in vitro. Chin J Integr Med 18: 431-436, 2012.
31. Shen AL, Hong F, Liu LY, Lin JM, Wei LH, Cai QY, Hong ZF and Peng J: Pien Tze Huang inhibits the proliferation of human colon carcinoma cells by arresting G1/S cell cycle progression. Oncol Lett 4: 767-770, 2012.
32. Shen AL, Chen YQ, Hong F, Lin JM, Wei LH, Hong ZF, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3. Oncol Rep 28: 2125-2130, 2012.
33. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F and Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577, 2000.
34. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863, 1996.
35. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
36. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78: 1379-1384, 1998.
37. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N and Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230, 2001.
38. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL and Jain RK: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609, 2001.
39. Sessa WC: eNOS at a glance. J Cell Sci 117: 2427-2429, 2004.
40. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V and Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in situ and invasive breast carcinomas. Clin Cancer Res 6: 2408-2416, 2000.
41. Aaltomaa SH, Lipponen PK and Kosma VM: Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 21: 3101-3106, 2001.